In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer

Leiphrakpam,Premila   D.; Agarwal,Ekta; Mathiesen,Michelle; Haferbier,Katie  L.; Brattain,Michael  G.; Chowdhury,Sanjib

doi:10.3892/or.2013.2819

In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer

Authors:
- Premila D. Leiphrakpam
- Ekta Agarwal
- Michelle Mathiesen
- Katie L. Haferbier
- Michael G. Brattain
- Sanjib Chowdhury
View Affiliations

Affiliations: Eppley Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198-5950, USA
Published online on: October 25, 2013 https://doi.org/10.3892/or.2013.2819
Pages: 87-94

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The development and characterization of effective anticancer drugs against colorectal cancer (CRC) is of urgent need since it is the second most common cause of cancer death. The study was designed to evaluate the effects of two IGF-1R antagonists, MK-0646, a recombinant fully humanized monoclonal antibody and OSI-906, a small molecule tyrosine kinase inhibitor on CRC cells. Xenograft study was performed on IGF-1R-dependent CRC cell lines for analyzing the antitumor activity of MK-0646 and OSI-906. Tumor proliferation and apoptosis were assessed using Ki67 and TUNEL assays, respectively. We also performed in vitro characterization of MK-0646 and OSI-906 treatment on CRC cells to identify mechanisms associated with drug-induced cell death. Exposure of the GEO and CBS tumor xenografts to MK-0646 or OSI-906 led to a decrease in tumor growth. TUNEL analysis showed an increase of approximately 45-55% in apoptotic cells in both MK-0646 and OSI-906 treated tumor samples. We report the novel finding that treatment with IGF-1R antagonists led to downregulation of X-linked inhibitor of apoptosis (XIAP) protein involved in cell survival and inhibition of cell death. In conclusion, IGF-1R antagonists (MK-0646 and OSI-906) demonstrated single agent inhibition of subcutaneous CRC xenograft growth. This was coupled to pro-apoptotic effects resulting in downregulation of XIAP and inhibition of cell survival. We report a novel mechanism by which MK-0646 and OSI-906 elicits cell death in vivo and in vitro. Moreover, these results indicate that MK-0646 and OSI-906 may be potential anticancer candidates for the treatment of patients with IGF-1R-dependent CRC.

View Figures

View References

1	Weber MM, Fottner C, Liu SB, Jung MC, Engelhardt D and Baretton GB: Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer. 95:2086–2095. 2002. View Article : Google Scholar : PubMed/NCBI
2	Maloney EK, McLaughlin JL, Dagdigian NE, et al: An anti-insulin growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63:5073–5083. 2003.PubMed/NCBI
3	Peters G, Gongoll S, Langner C, et al: IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 443:139–145. 2003. View Article : Google Scholar : PubMed/NCBI
4	Ewing GP and Goff LW: The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer. 9:219–223. 2010. View Article : Google Scholar : PubMed/NCBI
5	Asghar U, Hawkes E and Cunningham D: Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer. 9:274–281. 2010. View Article : Google Scholar : PubMed/NCBI
6	McKinley ET, Bugaj JE, Zhao P, et al: 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res. 17:3332–3340. 2011. View Article : Google Scholar : PubMed/NCBI
7	Goetsch L, Gonzalez A, Leger O, et al: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. 113:316–328. 2005. View Article : Google Scholar
8	Allison AS, McIntyre MA, McArdle C and Habib FK: The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion. Hum Pathol. 38:1590–1602. 2007. View Article : Google Scholar : PubMed/NCBI
9	Pollak MN, Schernhammer ES and Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 4:505–518. 2004. View Article : Google Scholar : PubMed/NCBI
10	Chowdhury S, Dominguez I, Sharratt E, Spernyak J, Brattain MG and Rajput A: Anti-tumor activity of IGF-1R kinase inhibitor PQIP in colon cancer. Clin Exp Pharmacol. S4:0052013.
11	Donovan EA and Kummar S: Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol. 66:91–98. 2008. View Article : Google Scholar : PubMed/NCBI
12	Atzori F, Traina TA, Ionta MT and Massidda B: Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol. 4:255–266. 2009. View Article : Google Scholar : PubMed/NCBI
13	Reidy-Lagunes DL, Vakiani E, Segal MF, et al: A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer. 118:4795–4800. 2012. View Article : Google Scholar : PubMed/NCBI
14	Reichert JM: Antibody-based therapeutics to watch in 2011. MAbs. 3:76–99. 2011. View Article : Google Scholar : PubMed/NCBI
15	King ER and Wong KK: Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov. 7:14–30. 2012. View Article : Google Scholar : PubMed/NCBI
16	Heidegger I, Pircher A, Klocker H and Massoner P: Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther. 11:701–707. 2011. View Article : Google Scholar : PubMed/NCBI
17	Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, et al: Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 1:1153–1171. 2009. View Article : Google Scholar : PubMed/NCBI
18	Buck E, Gokhale PC, Koujak S, et al: Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther. 9:2652–2664. 2010. View Article : Google Scholar : PubMed/NCBI
19	Brattain MG, Levine AE, Chakrabarty S, Yeoman LC, Willson JK and Long B: Heterogeneity of human colon carcinoma. Cancer Metastasis Rev. 3:177–191. 1984. View Article : Google Scholar
20	Boyd DD, Levine AE, Brattain DE, McKnight MK and Brattain MG: Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. Cancer Res. 48:2469–2474. 1988.PubMed/NCBI
21	Wang J, Yang L, Yang J, et al: Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res. 68:3152–3160. 2008. View Article : Google Scholar : PubMed/NCBI
22	Hu YP, Patil SB, Panasiewicz M, et al: Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. Cancer Res. 68:8004–8013. 2008. View Article : Google Scholar : PubMed/NCBI
23	Vanamala J, Reddivari L, Radhakrishnan S and Tarver C: Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer. 10:2382010. View Article : Google Scholar : PubMed/NCBI
24	Nakane PK: Recent progress in the peroxidase-labeled antibody method. Ann NY Acad Sci. 254:203–211. 1975. View Article : Google Scholar : PubMed/NCBI
25	Peruzzi F, Prisco M, Dews M, et al: Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol. 19:7203–7215. 1999.PubMed/NCBI
26	Ouban A, Muraca P, Yeatman T and Coppola D: Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 34:803–808. 2003. View Article : Google Scholar : PubMed/NCBI
27	Myers MG Jr, Grammer TC, Wang LM, et al: Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem. 269:28783–28789. 1994.
28	Kennedy SG, Wagner AJ, Conzen SD, et al: The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11:701–713. 1997. View Article : Google Scholar : PubMed/NCBI
29	Dan HC, Sun M, Kaneko S, et al: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem. 279:5405–5412. 2004. View Article : Google Scholar : PubMed/NCBI
30	Chowdhury S, Howell GM, Rajput A, et al: Identification of a novel TGFbeta/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS One. 6:e193352011. View Article : Google Scholar : PubMed/NCBI
31	Dohi T, Xia F and Altieri DC: Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell. 27:17–28. 2007. View Article : Google Scholar : PubMed/NCBI
32	Chowdhury S, Howell GM, Teggart CA, et al: Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J Biol Chem. 286:30937–30948. 2011. View Article : Google Scholar
33	Watson DS, Brotherick I, Shenton BK, Wilson RG and Campbell FC: Growth dysregulation and p53 accumulation in human primary colorectal cancer. Br J Cancer. 80:1062–1068. 1999. View Article : Google Scholar : PubMed/NCBI
34	Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S and Couture J: Molecular biology of colorectal cancer. Curr Probl Cancer. 21:233–300. 1997. View Article : Google Scholar
35	Moschos SJ and Mantzoros CS: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology. 63:317–332. 2002. View Article : Google Scholar : PubMed/NCBI
36	Sulkowski S, Kanczuga-Koda L, Koda M, Wincewicz A and Sulkowska M: Insulin-like growth factor-I receptor correlates with connexin 26 and Bcl-xL expression in human colorectal cancer. Ann NY Acad Sci. 1090:265–275. 2006. View Article : Google Scholar : PubMed/NCBI
37	Wu KD, Zhou L, Burtrum D, Ludwig DL and Moore MA: Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother. 56:343–357. 2007.PubMed/NCBI
38	Hakam A, Yeatman TJ, Lu L, et al: Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol. 30:1128–1133. 1999. View Article : Google Scholar : PubMed/NCBI
39	Reinmuth N, Liu W, Fan F, et al: Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res. 8:3259–3269. 2002.PubMed/NCBI
40	Sachdev D and Yee D: The IGF system and breast cancer. Endocr Relat Cancer. 8:197–209. 2001. View Article : Google Scholar
41	Surmacz E: Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia. 5:95–105. 2000. View Article : Google Scholar : PubMed/NCBI
42	Buck E, Eyzaguirre A, Rosenfeld-Franklin M, et al: Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 68:8322–8332. 2008. View Article : Google Scholar : PubMed/NCBI
43	Gualberto A and Karp DD: Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer. 10:273–280. 2009. View Article : Google Scholar : PubMed/NCBI
44	Shang Y, Mao Y, Batson J, et al: Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther. 7:2599–2608. 2008. View Article : Google Scholar : PubMed/NCBI
45	Zha J and Lackner MR: Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res. 16:2512–2517. 2010. View Article : Google Scholar : PubMed/NCBI
46	Chitnis MM, Yuen JS, Protheroe AS, Pollak M and Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 14:6364–6370. 2008. View Article : Google Scholar : PubMed/NCBI
47	Agarwal E, Brattain MG and Chowdhury S: Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
48	Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T and Altieri DC: IAP regulation of metastasis. Cancer Cell. 17:53–64. 2010. View Article : Google Scholar